bioRxivCancer BiologyPreprint
Transcriptional landscape of PTEN loss in primary prostate cancer
E. L. Imada, D. F. Sanchez, W. Dinalankara, T. Vidotto, E. M. Ebot, S. Tyekucheva, G. R. Franco, L. Mucci, M. Loda, E. M. Schaeffer, T. Lotan, L. Marchionni
Abstract
PTEN is the most frequently lost tumor suppressor in primary prostate cancer (PCa) and its loss is associated with aggressive disease. However, the transcriptional changes associated with PTEN loss in PCa have not been described in detail. Here, we applied a meta-analysis approach, leveraging two large PCa cohorts with experimentally validated PTEN and ERG status, to derive a transcriptomic signature of PTEN loss, while also accounting for potential confounders due to ERG rearrangements. Strikingly, the signature indicates a strong activation of both innate and adaptive immune systems upon PTEN loss, as well as an expected activation of cell-cycle genes. Moreover, we made use of our recently developed FC-R2 expression atlas to expand this signature to include many non-coding RNAs recently annotated by the FANTOM consortium. With this resource, we analyzed the TCGA-PRAD cohort, creating a comprehensive transcriptomic landscape of PTEN loss in PCa that comprises both the coding and an extensive non-coding counterpart.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Transcriptional network analysis of PTEN protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication
Ivana Rondon‐Lorefice, Jose Ignacio Lopez, … Isabel Mendizabal·Molecular OncologyPeer-reviewed·Nov 17, 2025
- Pan-genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome
T. Vidotto, C. M Melo, … J. Squire·bioRxiv·Sep 16, 2022
- Loss of tristetraprolin activates NF-κB induced phenotypic plasticity and primes transition to lethal prostate cancer
K. L. Morel, A. A. Hamid, … L. Ellis·bioRxiv·Aug 5, 2022
- Genome-wide analyses of transcription factors and co-regulators across seven cohorts identified reduced PPARGC1A expression as a driver of prostate cancer progression
M. Siddappa, S. A. Wani, … M. J. Campbell·bioRxiv·May 12, 2020
- Principal component analysis of RNA-seq data unveils a novel prostate cancer-associated gene expression signature
Y. Perera Negrin, A. Gonzalez, R. Perez·bioRxiv·Oct 26, 2020
- Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis
K. K. Chaudagar, H. Hieromnimon, … A. Patnaik·bioRxiv·May 23, 2023